Program
Insulin
Also written as “Inhaled Insulin”, “Subcutaneous Insulin” and “Inhaled insulin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Non-alcoholic Fatty Liver Disease · Drug-Related Side Effects and Adverse Reactions, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 110 open or running | phase 4since Jan 3, 2007 | Aug 22, 2005 | none ahead |
| Oramed | 50 open or running | phase 3since Oct 22, 2020 | Jun 19, 2013 | none ahead |
| Eli Lilly | 40 open or running | phase 3since Oct 19, 2006 | Jun 20, 2003 | none ahead |
| Oshadi Drug Administration | 20 open or running | phase 2since Jan 17, 2013 | Jan 17, 2013 | none ahead |
| Sanofi | 20 open or running | phase 4since Jul 23, 2014 | Sep 2, 2010 | none ahead |
| Baxter Healthcare | 10 open or running | phase 1since Jul 31, 2006 | Jul 31, 2006 | none ahead |
| cpex-pharmaceuticals-inc | 10 open or running | phase 2since Feb 23, 2009 | Feb 23, 2009 | none ahead |
| generex-biotechnology-corp | 10 open or running | phase 3since Apr 24, 2008 | Apr 24, 2008 | none ahead |
| getz-pharma | 10 open or running | phase 4since Dec 16, 2021 | Dec 16, 2021 | none ahead |
| nastech-pharmaceutical-company-inc | 10 open or running | phase 2since Feb 7, 2008 | Feb 7, 2008 | none ahead |
| Profil Institut für Stoffwechselforschung | 10 open or running | phase 1since Sep 14, 2009 | Sep 14, 2009 | none ahead |
| qdose-limited | 10 open or running | phase 1since Jan 24, 2007 | Jan 24, 2007 | none ahead |
| Roger New | 10 open or running | phase 2since Jun 19, 2024 | Jun 19, 2024 | none ahead |
| Sam Chun Dang Pharm. | 11 open or running | phase 1since May 26, 2026 | May 26, 2026 | none ahead |
Also a collaborator on its studies: integrium, Alkermes, Kowa, nextrials-inc, eresearch-technology-inc, Hoffmann-La Roche, acm-pivotal-global-central-laboratory and Novo Nordisk.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Jun 20, 2003.
- Sep 14, 2009Profil Institut für Stoffwechselforschung's first study: phase 1 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT00982254 · 10 enrolled · Germany
- Sep 2, 2010Sanofi's first study: phase 3 study in Diabetes Mellitus, Type 1New to SanofiSanofi · NCT01194882 · 479 enrolled · Belgium, France, Netherlands and more
- Jan 17, 2013Oshadi Drug Administration's first study: phase 2 study in Diabetes Mellitus, Type 1New to Oshadi Drug AdministrationOshadi Drug Administration · NCT01772251 · 10 enrolled · Israel
- Jun 19, 2013Oramed's first study: phase 2 study in Diabetes Mellitus, Type 2New to OramedOramed · NCT01889667 · 30 enrolled · United States
- Oct 27, 2013Phase 2 study in Diabetes MellitusOshadi Drug Administration · NCT01973920 · 12 enrolled · Israel
- Jul 23, 2014Phase 4 study in Diabetes Mellitus, Type 2Sanofi · NCT02201004 · 211 enrolled · Japan
- Oct 27, 2015Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02588950 · 11 enrolled · United States
- Dec 24, 2015Phase 2 study in Non-alcoholic Fatty Liver DiseaseOramed · NCT02653300 · 10 enrolled · Israel
- Oct 31, 2019Phase 2 study in Diabetes Mellitus, Type 1Oramed · NCT04150107 · 30 enrolled · United States
- Oct 22, 2020Phase 3 study in Diabetes Mellitus, Type 2Oramed · NCT04606576 · 710 enrolled · United States
- Oct 28, 2020Phase 2 study in Non-alcoholic Fatty Liver DiseaseOramed · NCT04616014 · 7 enrolled · Belgium
- Dec 16, 2021getz-pharma's first study: phase 4 study in Drug-Related Side Effects and Adverse ReactionsNew to getz-pharmagetz-pharma · NCT05161741 · 238 enrolled · Pakistan
- Jun 19, 2024Roger New's first study: phase 2 study in Type 2 Diabetes Treated With InsulinNew to Roger NewRoger New · NCT06473662 · 153 enrolled · United Kingdom
- May 26, 2026Sam Chun Dang Pharm.'s first study: phase 1 study in Diabetes Mellitus, Type 1New to Sam Chun Dang Pharm.Sam Chun Dang Pharm. · NCT07634770 · 16 planned · Germany
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07634770Diabetes Mellitus, Type 1 · Germany | 1 | Recruiting | Sam Chun Dang Pharm. | Oct 2026 | 16 |
| NCT06473662Type 2 Diabetes Treated With Insulin · United Kingdom | 2 | Completed | Roger New | Jul 11, 2020 | 153 |
| NCT05161741Drug-Related Side Effects and Adverse Reactions · Pakistan | 4 | Completed | getz-pharma | Nov 30, 2022 | 238 |
| NCT04616014Non-alcoholic Fatty Liver Disease · Belgium | 2 | Completed | Oramed | Jul 1, 2022 | 7 |
| NCT04606576Diabetes Mellitus, Type 2 · United States | 3 | Terminated | Oramed | Jan 13, 2023 | 710 |
| NCT04150107Diabetes Mellitus, Type 1 · United States | 2 | Completed | Oramed | Feb 6, 2020 | 30 |
| NCT02653300Non-alcoholic Fatty Liver Disease · Israel | 2 | Completed | Oramed | Mar 1, 2020 | 10 |
| NCT02588950Diabetes Mellitus, Type 2 · United States | 1 | Terminated | Eli Lilly | May 25, 2017 | 11 |
| NCT02201004Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Sanofi | Jan 2016 | 211 |
| NCT01973920Diabetes Mellitus · Israel | 2 | Completed | Oshadi Drug Administration | Feb 2017 | 12 |
| NCT01889667Diabetes Mellitus, Type 2 · United States | 2 | Completed | Oramed | Nov 2013 | 30 |
| NCT01772251Diabetes Mellitus, Type 1 · Israel | 2 | Completed | Oshadi Drug Administration | Jun 2013 | 10 |
| NCT01194882Diabetes Mellitus, Type 1 · Belgium, France, Netherlands and more | 3 | Completed | Sanofi | Feb 1, 2018 | 479 |
| NCT00982254Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Profil Institut für Stoffwechselforschung | Nov 2001 | 10 |
| NCT00850161Diabetes Mellitus, Type 1 | 2 | Withdrawn | cpex-pharmaceuticals-inc | Aug 2009 | 0 |
| NCT00668850Diabetes Mellitus · United States, Bulgaria, Canada and more | 3 | UNKNOWN | generex-biotechnology-corp | Aug 2011 | 500 |
| NCT00624767Diabetes Mellitus · United States | 2 | Completed | nastech-pharmaceutical-company-inc | Apr 2008 | 18 |
| NCT00479258Diabetes Mellitus, Type 1 · United States | 3 | Terminated | Pfizer | Oct 2007 | 2 |
| NCT00426920Diabetes Mellitus · United States | 1 | UNKNOWN | qdose-limited | 14 | |
| NCT00418522Diabetes Mellitus, Type 2 · United States, Puerto Rico | 4 | Completed | Pfizer | Aug 2008 | 413 |
| NCT00391209Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | May 2008 | 379 |
| NCT00358553Healthy · Germany | 1 | Completed | Baxter Healthcare | ||
| NCT00282971Diabetes Mellitus, Type 2 · Canada, France, Greece and more | 3 | Terminated | Pfizer | Feb 19, 2008 | 354 |
| NCT00150410Diabetes Mellitus · United States, Australia, Brazil and more | 3 | Completed | Pfizer | 626 | |
| NCT00143338Diabetes Mellitus, Type 2 · United States | 2 | Completed | Pfizer | 20 | |
| NCT00143104Diabetes Mellitus, Type 1 · United States | 2 | Completed | Pfizer | 20 | |
| NCT00139659Asthma · United States, Brazil, Canada and more | 3 | Completed | Pfizer | Oct 2008 | 288 |
| NCT00138671Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Terminated | Pfizer | Sep 2008 | 105 |
| NCT00137046Diabetes Mellitus, Type 1 · United States, Argentina, Brazil and more | 3 | Terminated | Pfizer | Dec 2008 | 582 |
| NCT00136916Diabetes Mellitus · United States, Brazil, Canada and more | 3 | Terminated | Pfizer | Dec 2008 | 635 |
| NCT00134147Diabetes Mellitus · United States, Canada, France and more | 3 | Completed | Pfizer | 1,100 | |
| NCT00099515Diabetes Mellitus, Type 2 · United States, Argentina, Portugal and more | 2 | Completed | Eli Lilly | 97 | |
| NCT00063128Diabetes Mellitus, Type 1 · United States | 2 | Completed | Eli Lilly | 119 |
How it is read
Names in the registry
- “Insulin”, 13 entries
- “Inhaled Insulin”, 5 entries
- “Subcutaneous Insulin”, 3 entries
- “Inhaled insulin”, 3 entries
- “Inhaled Insulin (Exubera)”, 2 entries
Codes read as this program: LY041001.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 22 studies
- Diabetes Mellitus, Type 1, 12 studies
- Diabetes Mellitus, 8 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
- Drug-Related Side Effects and Adverse Reactions, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.